Article info

Download PDFPDF

Original research
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

Authors

  1. Correspondence to Dr Hafsah Nabi; hafsah.nabi{at}regionh.dk
View Full Text

Citation

Nabi H, Hendricks O, Jensen DV, et al
Infliximab biosimilar-to-biosimilar switching in patients with inflammatory rheumatic disease: clinical outcomes in real-world patients from the DANBIO registry

Publication history

  • Received July 5, 2022
  • Accepted October 12, 2022
  • First published November 23, 2022.
Online issue publication 
November 23, 2022
  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.